Home/Pipeline/Na ion channel TicTACs

Na ion channel TicTACs

Pain

PreclinicalActive

Key Facts

Indication

Pain

Phase

Preclinical

Status

Active

Company

Solu Therapeutics

About Solu Therapeutics

Solu Therapeutics is a private, clinical-stage biotech developing a groundbreaking platform that conjugates bifunctional small molecules to antibodies, creating novel drug classes like CyTACs and TicTACs. This approach allows targeting of previously inaccessible cell surface proteins, such as GPCRs, with enhanced specificity and pharmacokinetics. The company's lead asset, STX-0712, is in Phase 1 for chronic myelomonocytic leukemia (CMML), with a pipeline spanning oncology, immunology, and pain. Backed by experienced leadership and venture capital, Solu leverages an exclusive license from GSK and aims to rapidly advance programs from concept to clinic.

View full company profile

Therapeutic Areas

Oncology Immunology & Inflammation Pain

Other Pain Drugs

Drug	Company	Phase	Status
Oxycodone Patch	Avecho Biotechnology	Preclinical	Active
Oxymorphone Patch	Avecho Biotechnology	Preclinical	Active
Desmetramadol	Syntrix Pharmaceuticals	Clinical Development	Active
Diclofenac Potassium Powder for Oral Solution	Patrin Pharma	Approved	Active
CG001419	Cullgen	Phase 1	Active
Proprietary Pain Program(s)	Oblique Therapeutics	Pre-clinical	Active
Pain Management APIs	Noramco	Commercial	Active
Dipendium (Diclofenac Potassium)	NovaMedica	Approved	Active
Infusional Pain Management (e.g., Paracetamol)	Galenica Senese	Commercial	Active
NCEs for Pain Management	Ipca Laboratories	Preclinical/Discovery	Active
XEN1701	Xenon Pharmaceuticals	Phase 1	Clinical trial initiated